Candriam S.C.A. Aurinia Pharmaceuticals Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 21, 2019	SELL	$5.34 - $6.59 $694,200 - $856,700	-130,000 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$6.05 - $6.75 $166,375 - $185,625	-27,500 Reduced 17.46%	130,000 $852,000
Q2 2018 Aug 14, 2018	BUY	$5.06 - $6.36 $199,869 - $251,220	39,500 Added 33.47%	157,500 $887,000
Q3 2017 Nov 03, 2017	BUY	$5.71 - $6.9 $673,780 - $814,200	118,000	118,000 $740,000

227

58.9M

949K

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.16B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.